2029 Biosimilars Pharmaceuticals 
Vial
MARCH 1, 2024
Introduction Contract research organizations (CROs) are essential in pharmaceutical research and development (R&D). billion by 2029. By geographical region, the global CRO services market in 2023 was dominated by North America. By revenue, the largest CRO in the US was Thermo Fisher Scientific Inc., with full-year revenue of US$23.04
FDA Law Blog: Biosimilars
DECEMBER 3, 2023
state pharmaceutical assistance programs). Each phase-in policy allows eligible manufacturers to build up in a stepwise manner to the 10% and 20% applicable discounts by 2029 and 2031, respectively. After 2024, the PDP sponsors will pay the enrollees’ 5% coinsurance during the catastrophic phase.
Expert insights. Personalized for you.
52 
Let's personalize your content